Many factors regulate normal cerebral blood flow (CBF), including signaling molecules that are synthesized and released from cells in the vicinity of cerebral blood vessels. Pathological changes in the brain also affect CBF; for example, CNS inflammation can be accompanied by abnormalities in CBF that lead to life-threatening edema. The hypothesis to be tested by the experiments in this proposal is that endocannabinoids are synthesized by both perivascular microglia (resident immune cells of the brain) and cerebral endothelial cells and m CBF under both normal and pathological conditions. In addition, we hypothesize that endocannabinoids produce vasodilation via vascular smooth muscle (VSM) CB1 cannabinoid receptor activation. Support for this hypothesis includes our findings that: the CB1 cannabinoid receptor is expressed by cerebral arterial and arteriolar VSM cells; activation of the VSM CB1 receptorand results in inhibition of L-type calcium channels; cannabinoids vasodilate isolated cerebral vessels and increase CBF in vivo. Intact cerebral arteries synthesize endocannabinoids in response to microglial and endothelial activators, supporting the hypothesis that cells in the immediate vicinity of the VSM make endocannabinoids. In addition, microglial cells synthesize endocannabinoids in response to an activating stimulus, lipopolysaccharide (LPS). The primary model that we will use to approach this hypothesis is the isolated, middle cerebral artery from rat. We will also use atmospheric liquid chromatography-mass spectrometry to measure endocannabinoids and the in vivo significance of these findings will be explored using laser Doppler flowmetry.
The specific aims of this proposal are: (1) to characterize the role of the CB1 receptor in cerebral arterial vasomotor tone and responsiveness; (2) to determine the distribution of the CB1 receptor throughout the cerebral vasculature; (3) to determine the cellular sources and regulation of endocannabinoid production in isolated cerebral arteries; (4) to determine whether activated microglial cells induce CB1 receptor-dependent vasodilation cerebral arteries; and (5) to determine the contribution of VSM CB1 receptors in the regulation of cerebral blood flow in vivo. Activated microglial cells contribute to many neurodegenerative diseases and to the worsening of stroke and trauma. Increased understanding of the mediators that are released by activated microglia and their targets may provide new therapeutic approaches to CNS diseases with an inflammatory component.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041314-03
Application #
6845722
Study Section
Special Emphasis Panel (ZRG1-MDCN-4 (01))
Program Officer
Jacobs, Tom P
Project Start
2003-02-15
Project End
2007-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
3
Fiscal Year
2005
Total Cost
$285,000
Indirect Cost
Name
Medical College of Wisconsin
Department
Pharmacology
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Ho, W S Vanessa; Hill, Matthew N; Miller, Gregory E et al. (2012) Serum contents of endocannabinoids are correlated with blood pressure in depressed women. Lipids Health Dis 11:32
Ho, W-Sv; Patel, S; Thompson, J R et al. (2010) Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. Br J Pharmacol 160:736-46
Liou, Gregory I; Auchampach, John A; Hillard, Cecilia J et al. (2008) Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci 49:5526-31
Maresz, Katarzyna; Pryce, Gareth; Ponomarev, Eugene D et al. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492-7
Hillard, C J; Ho, W-Sv; Thompson, J et al. (2007) Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. Br J Pharmacol 152:691-8
Carrier, Erica J; Auchampach, John A; Hillard, Cecilia J (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103:7895-900
Rademacher, David J; Patel, Sachin; Ho, W-S Vanessa et al. (2005) U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance. Am J Physiol Heart Circ Physiol 288:H2694-701
Benito, Cristina; Kim, Woong-Ki; Kim, Wong-Ki et al. (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25:2530-6
Seagard, Jeanne L; Hopp, Francis A; Hillard, Cecilia J et al. (2005) Effects of endocannabinoids on discharge of baroreceptive NTS neurons. Neurosci Lett 381:334-9
Hillard, Cecilia J (2005) Lipids and drugs of abuse. Life Sci 77:1531-42

Showing the most recent 10 out of 11 publications